The alleged issues apply to only a small subset of the clinical sites/volunteers in the trial:
> In her 25 September email to the FDA Jackson wrote that Ventavia had enrolled more than 1000 participants at three sites. The full trial (registered under NCT04368728) enrolled around 44 000 participants across 153 sites that included numerous commercial companies and academic centres.
Ventavia looks sketchy, but this affects 1/44th of the patients and 3/153 of the sites. There's nothing to suggest they fudged the numbers in Pfizer's favor either, only that they were sloppy.